(S1 (S (S (NP (NP (JJ Immunological) (NN tolerance)) (PP (TO to) (NP (NNS self-antigens)))) (VP (VBZ is) (NP (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (DT the) (NN deletion)) (PP (IN of) (NP (NP (JJ self-reactive) (NN T) (NNS lymphocytes)) (PP (IN in) (NP (NP (DT the) (NN thymus)) (PRN (-LRB- -LRB-) (NP (JJ central) (NN tolerance)) (-RRB- -RRB-))))))))) (CC and) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (ADJP (RB potentially) (JJ self-reactive)) (NN T) (NNS lymphocytes))) (PP (IN in) (NP (NP (DT the) (NN periphery)) (PRN (-LRB- -LRB-) (NP (JJ peripheral) (NN tolerance)) (-RRB- -RRB-)))))))) (PRN (-LRB- -LSB-) (NP (CD 1)) (-RRB- -RSB-)))) (. .)))
(S1 (S (S (NP (NP (NN Suppression)) (PP (IN of) (NP (JJ pathogenic) (NN T) (NN cell) (NNS responses)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NP (NP (ADJP (RB naturally) (VBG arising)) (NN CD4+CD25+) (NN T) (JJ regulatory) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS Tregs)) (-RRB- -RRB-))) (PRN (-LRB- -LSB-) (NP (NN 2,3)) (-RRB- -RSB-))))))) (. .)))
(S1 (S (S (NP (NP (NNS Deficiencies)) (PP (IN in) (NP (NP (NN Treg) (NN development)) (CC and) (NP (NN function))))) (VP (VBP have) (VP (VBN been) (VP (VBN linked) (PP (TO to) (NP (NP (DT the) (JJ severe) (JJ autoimmune) (NN disorder)) (VP (VBN known) (PP (IN as) (NP (NP (JJ immune) (NN dysregulation)) (, ,) (NP (NN polyendocrinopathy)) (, ,) (NP (NN enteropathy)) (, ,) (NP (NP (JJ X-linked) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN IPEX)) (-RRB- -RRB-)))))))) (PRN (-LRB- -LSB-) (NP (CD 4)) (-RRB- -RSB-)))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ recent) (NNS studies)) (VP (VBP have) (VP (VBN provided) (NP (JJ strong) (NN evidence) (SBAR (IN that) (S (NP (NP (NN dysregulation)) (PP (IN of) (NP (NP (NN Treg) (NN development)) (CC and/or) (NP (NN function))))) (VP (MD may) (VP (VB be) (NP (DT a) (JJ significant) (NN factor)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (NP (JJ several) (JJ autoimmune) (NNS disorders)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NP (JJ multiple) (NN sclerosis)) (PRN (-LRB- -LSB-) (NP (CD 5)) (-RRB- -RSB-))) (, ,) (NP (NP (NN myasthenia) (NN gravis)) (PRN (-LRB- -LSB-) (NP (CD 6)) (-RRB- -RSB-))) (, ,) (CC and) (NP (NP (NN type) (CD 1) (NN diabetes)) (PRN (-LRB- -LSB-) (NP (CD 7)) (-RRB- -RSB-))))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ virus-induced) (JJ immunologic) (NNS disorders)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NP (ADJP (NP (NP (JJ human) (NN T) (NN lymphotropic) (NN virus) (NN type) (CD I)) (PRN (-LRB- -LSB-) (NP (NN HTLV-I)) (-RRB- -RSB-))) (JJ -associated)) (JJ myelopathy/tropical) (JJ spastic) (NN paraparesis)) (PRN (-LRB- -LSB-) (NP (NN HAM/TSP)) (-RRB- -RSB-))) (, ,) (CC and) (NP (NP (JJ HIV-induced) (NN AIDS)) (PRN (-LRB- -LSB-) (NP (CD 8-10)) (-RRB- -RSB-))))) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN transcription) (NN factor) (NN Foxp3)) (VP (VP (VBZ is) (NP (NP (DT a) (JJ 431-amino) (NN acid) (-LRB- -LRB-) (JJ 48-kDa) (-RRB- -RRB-) (NN protein)) (VP (VBN expressed) (PP (IN at) (NP (NP (ADJP (RB very) (JJ high)) (NNS levels)) (PP (IN in) (NP (NN CD4+CD25hi) (NN T) (NNS cells)))))))) (CC and) (VP (VBZ has) (ADVP (RB previously)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADVP (RB absolutely)) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN Treg) (NN development)) (CC and) (NP (NN function) (-LRB- -LSB-) (CD 11-14) (-RRB- -RSB-))))))))))))) (. .)))
(S1 (S (S (NP (NN Foxp3)) (VP (VBZ contains) (NP (NP (NP (DT a) (JJ proline-rich) (JJ amino-terminal) (NN domain)) (VP (VBN reported) (S (VP (TO to) (VP (VB function) (PP (IN as) (NP (NP (NP (NP (DT a) (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-))) (CC and) (NP (JJ nuclear) (NN factor-kappaB) (-LRB- -LRB-) (NN NF-kappaB) (-RRB- -RRB-) (NN binding) (NN domain))))))))) (, ,) (NP (NP (DT a) (JJ central) (NN region)) (VP (VBG containing) (NP (NP (NP (DT a) (NN zinc) (NN finger)) (CC and) (NP (NN leucine) (NN zipper))) (ADJP (RB potentially) (JJ important) (PP (IN for) (NP (JJ protein-protein) (NNS interactions))))))) (, ,) (CC and) (NP (NP (DT a) (JJ carboxyl-terminal) (NN forkhead) (-LRB- -LRB-) (NN FKH) (-RRB- -RRB-) (NN domain)) (VP (VBN required) (PP (IN for) (NP (NP (JJ nuclear) (NN localization)) (CC and) (NP (NP (JJ DNA-binding) (NN activity)) (PRN (-LRB- -LSB-) (NP (CD 14-16)) (-RRB- -RSB-)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Functional) (NN inactivation)) (PP (IN of) (NP (NN Foxp3))) (PP (IN by) (NP (NP (JJ genetic) (NNS mutations)) (VP (VBG affecting) (NP (NP (NP (DT the) (NN Foxp3) (NN coding) (NN region)) (PRN (, ,) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN in) (NP (NN IPEX)))))) (, ,))) (CC or) (NP (NP (NN repression)) (PP (IN of) (NP (NN Foxp3) (NN expression))) (PP (IN by) (NP (DT the) (JJ HTLV-I-encoded) (NN transactivator) (NN protein) (NN Tax)))))))) (, ,) (SBAR (IN as) (S (ADVP (RB recently)) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN HAM/TSP)))))))) (, ,)) (VP (VBZ results) (PP (IN in) (NP (NP (NN loss)) (PP (IN of) (NP (NP (JJ regulatory) (NN activity)) (PP (IN in) (NP (NP (NN CD4+CD25hi) (NN T) (NNS cells)) (PRN (-LRB- -LSB-) (NP (NN 4,8,17)) (-RRB- -RSB-)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ clear)) (SBAR (IN that) (S (NP (NN Foxp3)) (VP (VBZ regulates) (NP (NP (NN T) (NN cell) (NN proliferation)) (CC and) (NP (NN cytokine) (NN production))))))))) (, ,) (NP (RB very) (JJ little)) (VP (VBZ is) (VP (VBN known) (S (VP (VBG concerning) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NN Foxp3) (NN function))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ first) (NN evidence)) (VP (TO to) (VP (VB indicate) (SBAR (WHADVP (WRB how)) (S (NP (NN Foxp3)) (VP (VBZ promotes) (NP (NP (DT the) (NP (NN development)) (CC and) (NP (NN function))) (PP (IN of) (NP (JJ regulatory) (NN T) (NNS cells)))))))))) (VP (VBD came) (PP (IN from) (NP (DT a) (NN report))) (PP (IN by) (NP (NP (NP (NP (NNP Ziegler)) (CC and) (NP (NNS colleagues))) (PRN (-LRB- -LSB-) (NP (CD 16)) (-RRB- -RSB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD suggested) (SBAR (IN that) (S (NP (NN Foxp3)) (VP (MD could) (VP (VB inhibit) (NP (JJ transcriptional) (NN activation)) (PP (IN by) (S (ADVP (RB physically)) (VP (VBG interacting) (PP (IN with) (NP (NP (NN forkhead) (NN binding) (NNS sites)) (ADJP (JJ located) (RB immediately) (JJ adjacent) (PP (TO to) (NP (NP (JJ critical) (JJ cis-acting) (NN NF-AT) (NN binding) (NNS sites)) (VP (VBN found) (PP (IN in) (NP (NP (JJ various) (NN cytokine) (NNS promoters)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN IL-2) (NN promoter)) (-RRB- -RRB-)))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT That) (NN study)) (ADVP (RB also)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN Foxp3)) (VP (MD could) (VP (VB repress) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT a) (JJ synthetic) (NN reporter) (NN vector)) (VP (VBG containing) (NP (NP (DT an) (NN SV40) (NN promoter)) (CC and) (NP (NP (CD three) (JJ tandem) (NNS copies)) (PP (IN of) (NP (DT a) (NN forkhead) (NN binding) (NN site))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBD provided) (NP (NP (JJ additional) (NN evidence)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN Foxp3) (JJ transcriptional) (NN repression)) (VP (VBD was) (VP (VBN mediated) (PP (IN by) (S (VP (VBG binding) (PP (IN in) (NP (DT a) (JJ sequence-specific) (NN manner))) (PP (TO to) (NP (NP (NNS promoters)) (VP (VBG containing) (NP (NN forkhead) (NN binding) (NNS sites)))))))))))))))) (. .)))
(S1 (S (NP (NP (DT A) (JJ recent) (NN study)) (PP (IN by) (NP (NP (NNP Bettelli)) (CC and) (NP (NNS colleagues)))) (PRN (-LRB- -LSB-) (NP (CD 15)) (-RRB- -RSB-))) (ADVP (RB further)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN Foxp3)) (VP (MD could) (VP (VB inhibit) (NP (NP (NP (NN NF-AT)) (CONJP (RB as) (RB well) (IN as)) (NP (NN NF-kappaB))) (NN activation)) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN suppression)))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB involve) (NP (NP (JJ direct) (JJ protein-protein) (NNS interactions)) (PP (IN between) (NP (NP (NN NF-AT)) (CC or) (NP (NP (NN NF-kappaB)) (CC and) (NP (NN Foxp3))) (CONJP (RB rather) (IN than)) (NP (NP (NN binding)) (PP (IN of) (NP (NN Foxp3))) (PP (TO to) (NP (NP (NN promoter) (NNS elements)) (ADJP (JJ adjacent) (PP (TO to) (NP (JJ cis-acting) (NP (NP (NN NF-AT)) (CC or) (NP (NN NF-kappaB))) (NNS sites)))))))))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Collectively)) (, ,) (NP (DT these) (NNS data)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NN Foxp3)) (VP (MD may) (VP (VB function) (PP (IN as) (NP (NP (DT a) (JJ transcriptional) (NN repressor)) (, ,) (VP (ADVP (RB potentially)) (PP (IN through) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (DT both) (JJ DNA-protein) (CC and) (JJ protein-protein) (NNS interactions)))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBN expanded) (PP (IN upon) (NP (DT these) (NNS observations))) (PP (IN by) (S (VP (VBG defining) (NP (NP (JJ additional) (NNS requirements)) (PP (IN of) (NP (NP (JJ Foxp3-mediated) (NN repression)) (PP (IN of) (NP (NN NF-kappaB) (NN activation)))))))))) (, ,) (CC and) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN Foxp3)) (VP (MD could) (VP (VB target) (NP (JJ additional) (NN signaling) (NNS pathways)) (PP (IN by) (S (VP (VBG examining) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (ADJP (ADJP (JJ NF-kappaB-dependent)) (CC and) (ADJP (NN NF-kappaB-independent) (JJ retroviral))) (NNS pathogens))))))))))))) (. .)))
(S1 (S (NP (NP (NP (DT The) (NN characterization)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS targets)) (PP (IN of) (NP (NN Foxp3)))))) (CC and) (NP (NP (DT the) (NN mechanism-LRB-s-RRB-)) (VP (VBN utilized) (PP (IN by) (NP (NP (NN Foxp3)) (VP (TO to) (VP (VB support) (NP (NP (NN Treg) (NN development)) (CC and) (NP (NN function)))))))))) (VP (MD will) (VP (VB aid) (PP (IN in) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (DT the) (NN role) (S (NP (NNS Tregs)) (VP (VBP play) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ human) (JJ autoimmune) (NN disease))))))))))))) (. .)))
